Unicycive Therapeutics (UNCY) Short term Debt (2020 - 2024)
Unicycive Therapeutics posted quarterly Short term Debt of $208000.0 for Q1 2024, down 100.0% on a QoQ basis from $10.1 billion in Q2 2023.
Unicycive Therapeutics (UNCY) has 4 years of Short term Debt data on file, last reported at $208000.0 in Q1 2024.
- For the quarter ending Q1 2024, Short term Debt changed N/A year-over-year to $208000.0; the trailing twelve-month figure through Mar 2024 stood at $208000.0 (changed N/A YoY), and the FY2020 full-year result was $967000.0, changed N/A from the prior year.
- Short term Debt for Q1 2024 stood at $208000.0, down from $10.1 billion in the prior quarter.
- Across five years, Short term Debt topped out at $10.1 billion in Q2 2023 and bottomed at $103000.0 in Q3 2021.
- The 4-year median for Short term Debt is $901000.0 (2021), against an average of $2.0 billion.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 208,000.00 |
| Jun 30, 2023 | 10.09 Bn |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 901,000.00 |
| Dec 31, 2020 | 967,000.00 |